ased 12%, including a 3% favorable foreign
exchange impact, to $19.3 billion compared to the same period in 2006. Net
earnings from continuing operations in the twelve months of 2007 on a GAAP
basis were $2.0 billion, or $0.99 per diluted share, compared to $1.4
billion, or $0.73 per diluted share for the same period last year. On a
non-GAAP basis, excluding specified items, Bristol-Myers Squibb reported
net earnings from continuing operations of $2.7 billion, or $1.38 per
diluted share for the twelve months ended December 31, 2007, compared to
$2.0 billion, or $1.01 per diluted share for the same period last year.
Included in discontinued operations were Medical Imaging full year 2007 and
2006 net sales of $629 million and $658 million, respectively, and basic
and diluted earnings per share of $0.10 and $0.08 in 2007 and 2006,
NEW PRODUCT AND PIPELINE DEVELOPMENTS
In December, the European Commission granted marketing authorization
for ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil
fumarate 300 mg), formally approving ATRIPLA(R) for commercialization in
the 27 countries of the European Union, as well as in Norway and Iceland.
ATRIPLA(R) has been launched in the United Kingdom, Germany and Austria.
In December, Bristol-Myers Squibb and Medarex, Inc. announced top-line
data from three registrational trials that constitute the monotherapy
program for ipilimumab in patients with metastatic melanoma. The companies
plan to meet with regulatory agencies in the near future to discuss
possible regulatory pathways forward based on these data.
In November, Bristol-Myers Squibb and Pierre Fabre Medicament announced
the termination of the license agreement for the development of vinflunine,
a chemotherapy agent under investigation for the treatment of advanced or
metastatic bladder cancer and other tumor types.
In November, ABILIFY(R) (aripiprazole) was approved by the Food and
Drug Administration (FDA) as
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Related medicine news :1
|SOURCE Bristol-Myers Squibb Company|
Copyright©2008 PR Newswire.
All rights reserved
. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging2
. Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors3
. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone4
. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan5
. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb6
. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 257
. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices8
. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing9
. Bristol-Myers Squibb Announces Dividend10
. P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company11
. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II